Drugs Made In America Acquisition (DMII) Non-Current Deffered Revenue (2025)
Drugs Made In America Acquisition (DMII) posted quarterly Non-Current Deffered Revenue of $17.5 million for Q4 2025, little changed quarter-over-quarter from $17.5 million in Q3 2025.
Drugs Made In America Acquisition (DMII) Non-Current Deffered Revenue (2025) Analysis & Trends
Drugs Made In America Acquisition (DMII) has reported Non-Current Deffered Revenue for 1 consecutive years, with $17.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Deffered Revenue changed N/A year-over-year to $17.5 million; the TTM figure through Dec 2025 stood at $17.5 million (changed N/A YoY), while the FY2025 annual figure was $17.5 million, changed N/A from the prior year.
- Non-Current Deffered Revenue held at $17.5 million in Q4 2025 per DMII's latest filing, from $17.5 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $17.5 million in Q3 2025 and bottomed at $17.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oxley Bridge Acquisition | 585.76 Mn | 585.76 Mn | - | - |
| 2 | Launch Two Acquisition | 557.86 Mn | 557.86 Mn | - | - |
| 3 | Drugs Made In America Acquisition | 507.00 Mn | 507.00 Mn | - | 17.50 Mn |
| 4 | Cantor Equity Partners IV | 468.00 Mn | 468.00 Mn | - | - |
| 5 | GP-Act III Acquisition | 401.06 Mn | 401.06 Mn | - | 13.69 Mn |
| 6 | Aldel Financial | 397.49 Mn | 397.49 Mn | - | - |
| 7 | Republic Digital Acquisition | 389.25 Mn | 388.51 Mn | - | - |
| 8 | Gores Holdings X | 385.06 Mn | 384.87 Mn | - | 10.76 Mn |
| 9 | Agriculture & Natural Solutions Acquisition | 377.29 Mn | 377.04 Mn | - | 12.08 Mn |
| 10 | CSLM Digital Asset Acquisition Corp III | 322.52 Mn | 314.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 17.50 Mn |
| Sep 30, 2025 | 17.50 Mn |